Neurotherapeutics

, Volume 14, Issue 1, pp 62–68

Tau Imaging in Alzheimer’s Disease Diagnosis and Clinical Trials

  • Jared R. Brosch
  • Martin R. Farlow
  • Shannon L. Risacher
  • Liana G. Apostolova
Review

DOI: 10.1007/s13311-016-0490-y

Cite this article as:
Brosch, J.R., Farlow, M.R., Risacher, S.L. et al. Neurotherapeutics (2017) 14: 62. doi:10.1007/s13311-016-0490-y

Abstract

In vivo imaging of the tau protein has the potential to aid in quantitative diagnosis of Alzheimer’s disease, corroborate or dispute the amyloid hypothesis, and demonstrate biomarker engagement in clinical drug trials. A host of tau positron emission tomography agents have been designed, validated, and tested in humans. Several agents have characteristics approaching the ideal imaging tracer with some limitations, primarily regarding off-target binding. Dozens of clinical trials evaluating imaging techniques and several pharmaceutical trials have begun to integrate tau imaging into their protocols.

Keywords

Alzheimer’s disease Tau Tau imaging 

Supplementary material

13311_2016_490_MOESM1_ESM.pdf (1.2 mb)
ESM 1(PDF 1225 kb)
13311_2016_490_MOESM2_ESM.pdf (1.2 mb)
ESM 2(PDF 1197 kb)

Copyright information

© The American Society for Experimental NeuroTherapeutics, Inc. 2016

Authors and Affiliations

  • Jared R. Brosch
    • 1
  • Martin R. Farlow
    • 1
  • Shannon L. Risacher
    • 2
  • Liana G. Apostolova
    • 1
    • 2
    • 3
  1. 1.Department of NeurologyIndiana University School of MedicineIndianapolisUSA
  2. 2.Department of Radiological SciencesIndiana University School of MedicineIndianapolisUSA
  3. 3.Department of Medical and Molecular GeneticsIndiana University School of MedicineIndianapolisUSA

Personalised recommendations